Commencing operations in October 2010, the new facility, under full AAALAC accreditation, will provide non-GLP and GLP specialist pharmacology services to the global pharmaceutical and biotech industry. Services will complement those provided by the parent company headquartered in France and will initially focus on abuse liability assessment of new Chemical and Biological Entities (NCEs and NBEs) in non-human primates.
Using new purpose-designed laboratories, Porsolt Inc. (USA) will build on an already existing 15-year partnership with the University of Texas in San Antonio. Dr. Mark S. Duxon, Chief Executive Officer of Porsolt said “the creation of a Research Centre in the USA is one of several exciting and landmark developments for Porsolt in 2010/2011. Porsolt’s US business has always been significant and currently represents 30% of our global sales each year. This Research Centre further emphasizes our commitment to the US market whilst providing our global client base with increased capacity for the bespoke services they require. Like all companies in the preclinical CRO space, Porsolt has fought hard to maintain sales and revenue throughout 2008 and 2009. However, the commitment of Porsolt to be a solution provider in boutique pharmacology, dedicated to giving clients what they need on time, has enabled us to execute an expansion strategy in the USA and Europe. Our intention is to develop our services in the USA in line with demand, initially focusing on cross-species abuse liability to GLP standards”.
Dr. Roger D. Porsolt, President and founder of Porsolt said “possessing our own Research Centre in the USA fulfils a longstanding ambition to provide services to our expanding list of US sponsors. Since our inception over 25 years ago, we have sought to establish ourselves as internationally recognized scientific experts in pharmacology and have already had considerable success in attracting North American clients. Possessing our own research site on the North American continent will reinforce this and should open the way for US public bodies and private US research foundations to benefit from our services. Although our initial thrust will be in the area of drug abuse/dependence, we intend to expand rapidly to cover other major medical areas including cognitive, pain, inflammatory, schizophrenia, respiratory and cardiovascular pharmacology”.
Scientist-to-Scientist for your Projects
About Porsolt SAS (Porsolt & Partners Pharmacology)
Porsolt is a long established preclinical CRO, having started operations in 1984 under the name ITEM-Labo. Porsolt has obtained an international reputation for expertise in physio- pathological models, customized procedures and tailored solutions for discovering treatments of psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, and metabolic and eating disorders. Porsolt also offers services for safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration in full compliance with GLP (ICH S7), including full assessment of arrhythmogenic risk and abuse and dependence liability.
Porsolt is located in France with facilities in Paris and Laval. For additional information about the organisation, please visit www.porsolt.com or email us at contact@porsolt.com
